Chapitre 30 · Pharmaceutical products

3006.92.90

Other

  1. 3006 Pharmaceutical goods specified in Note 4 to this Chapter
  2. - Other:
  3. 3006.92 - - Waste pharmaceuticals:
  4. - - - Other

Các mặt hàng dược phẩm ghi trong Chú giải 4 của Chương này / - Loại khác: / - - Phế thải dược phẩm: / - - - Loại khác

Unité: kg/unit Niveau: Ligne à 8 chiffres Source: BT2026 ligne 4686 SOURCE

Taxes applicables en 2026

Source : tarif consolidé BT2026 (mis à jour le 05/04/2026)
Droit d'importation ordinaire 21% 15/2023/QĐ-TTg · 15/07/2023
Préférentiel (NPF) 14% 26/2023/NĐ-CP · 15/07/2023
TVA 5 / 8 / 10 (plusieurs taux) 181/2025/NĐ-CP · 01/07/2025
Taxe spéciale de consommation Aucune donnée
Taxe environnementale Aucune donnée
Droit d'exportation Aucune donnée

Taux préférentiels spéciaux (ALE) – 2026

FTATauxBase des donnéesPreuve de l'origineBase juridiqueStatut
CPTPP 2,7% · M: 4% Plus bas publié Tarif consolidé BT2026
(VI)
CPTPP 115/2022/NĐ-CP Ad valorem
EVFTA 5% Tarif consolidé BT2026
2026
EUR.1 116/2022/NĐ-CP Ad valorem
UKVFTA 5% Tarif consolidé BT2026
2026
EUR.1 117/2022/NĐ-CP Ad valorem
VIFTA 9,8% Tarif consolidé BT2026
2026
Form VI (verify) 131/2024/NĐ-CP Ad valorem
VKFTA 14% Tarif consolidé BT2026
2026
VK 125/2022/NĐ-CP Ad valorem
VN-LAO 14% Tarif consolidé BT2026 S 206/2025/NĐ-CP Ad valorem
VN-CAM Aucune donnée Aucune donnée S 56/2026/NĐ-CP Aucune donnée
VNCU Aucune donnée Aucune donnée VNCB · Form VC (Cuba) 114/2022/NĐ-CP Aucune donnée
AANZFTA * non éligible Tarif consolidé BT2026
2022 - 2027 (một mức cho cả giai đoạn)
AANZ 121/2022/NĐ-CP Non éligible (*)
ACFTA * non éligible Tarif consolidé BT2026
2022 - 2027 (một mức cho cả giai đoạn)
E 118/2022/NĐ-CP Non éligible (*)
AHKFTA * non éligible Tarif consolidé BT2026
2026
AHK 123/2022/NĐ-CP Non éligible (*)
AIFTA * non éligible Tarif consolidé BT2026
01/01/2026 - 31/12/2026
AI 122/2022/NĐ-CP Non éligible (*)
AJCEP * non éligible Tarif consolidé BT2026
01/4/2026 - 31/3/2027
AJ 120/2022/NĐ-CP Non éligible (*)
AKFTA * non éligible Tarif consolidé BT2026
2022 - 2027 (một mức cho cả giai đoạn)
AK 119/2022/NĐ-CP Non éligible (*)
ATIGA * non éligible Tarif consolidé BT2026
2026
D 126/2022/NĐ-CP Non éligible (*)
RCEP (Annexe A)
BN, KH, ID, LA, MY, MM, PH, SG, TH
* non éligible Tarif consolidé BT2026
2026
RCEP Form / Declaration of origin 129/2022/NĐ-CP Non éligible (*)
RCEP (Annexe B)
AU
* non éligible Tarif consolidé BT2026
2026
RCEP Form / Declaration of origin 129/2022/NĐ-CP Non éligible (*)
RCEP (Annexe C)
CN
* non éligible Tarif consolidé BT2026
2026
RCEP Form / Declaration of origin 129/2022/NĐ-CP Non éligible (*)
RCEP (Annexe D)
JP
* non éligible Tarif consolidé BT2026
2026
RCEP Form / Declaration of origin 129/2022/NĐ-CP Non éligible (*)
RCEP (Annexe E)
KR
* non éligible Tarif consolidé BT2026
2026
RCEP Form / Declaration of origin 129/2022/NĐ-CP Non éligible (*)
RCEP (Annexe F)
NZ
* non éligible Tarif consolidé BT2026
2026
RCEP Form / Declaration of origin 129/2022/NĐ-CP Non éligible (*)
VCFTA * non éligible Tarif consolidé BT2026
2026
VC 112/2022/NĐ-CP Non éligible (*)
VJEPA * non éligible Tarif consolidé BT2026
01/4/2026 - 31/3/2027
JV · Form VJ 124/2022/NĐ-CP Non éligible (*)
VN-EAEU * non éligible Tarif consolidé BT2026
2026
EAV 113/2022/NĐ-CP Non éligible (*)

Un taux publié ne signifie pas que les marchandises sont éligibles. Le respect des règles d'origine et une preuve de l'origine valide sont requis.

Lancer le Smart Tariff Advisory Comparer les ALE Calculer les taxes

Historique des taux / démantèlement par année

D'après les feuilles des listes ALE 2022–2027
FTAPériodes
ACFTA
AC · ligne 4610
2022 - 2027 (một mức cho cả giai đoạn)* non éligible
ATIGA
AT · ligne 4571
2022* non éligible 2023* non éligible 2024* non éligible 2025* non éligible 2026* non éligible 2027* non éligible
AJCEP
AJ · ligne 4609
30/12/2022 - 31/3/2023* non éligible 01/4/2023 - 31/3/2024* non éligible 01/4/2024 - 31/3/2025* non éligible 01/4/2025 - 31/3/2026* non éligible 01/4/2026 - 31/3/2027* non éligible 01/4/2027 - 31/3/2028* non éligible
VJEPA
VJ · ligne 4613
30/12/2022 - 31/3/2023* non éligible 01/4/2023 - 31/3/2024* non éligible 01/4/2024 - 31/3/2025* non éligible 01/4/2025 - 31/3/2026* non éligible 01/4/2026 - 31/3/2027* non éligible 01/4/2027 - 31/3/2028* non éligible
AKFTA
AK · ligne 4613
2022 - 2027 (một mức cho cả giai đoạn)* non éligible
Taux avec exclusions: *
AANZFTA
AANZ · ligne 4577
2022 - 2027 (một mức cho cả giai đoạn)* non éligible
Colonne de taux F (masquée): *
AIFTA
AI · ligne 4573
30/12/2022* non éligible 31/12/2022 - 30/12/2023* non éligible 31/12/2023 - 30/12/2024* non éligible 31/12/2024 - 31/12/2025* non éligible 01/01/2026 - 31/12/2026* non éligible 01/01/2027 - 31/12/2027* non éligible
VKFTA
VK · ligne 4573
202214% 202314% 202414% 202514% 202614% 202714%
VCFTA
VC · ligne 4620
2022* non éligible 2023* non éligible 2024* non éligible 2025* non éligible 2026* non éligible 2027* non éligible
VN-EAEU
EAV · ligne 4617
2022* non éligible 2023* non éligible 2024* non éligible 2025* non éligible 2026* non éligible 2027* non éligible
AHKFTA
AKH · ligne 4625
2022* non éligible 2023* non éligible 2024* non éligible 2025* non éligible 2026* non éligible 2027* non éligible
EVFTA
EV-NK · ligne 4596
202210,1% 20238,9% 20247,6% 20256,3% 20265% 20273,8%
Indicateur de modification (auxiliaire): X
UKVFTA
UKV · ligne 4598
202210,1% 20238,9% 20247,6% 20256,3% 20265% 20273,8%
Indicateur de modification (auxiliaire): X
CPTPP
CPTPP · ligne 4596
(I) → 2021*9,5% (II) → 2022*8,1% (III) → 2023*6,8% (IV) → 2024*5,4% (V) → 2025*4% (VI) → 2026*2,7% (VII) → 2027*1,3%
RCEP A
RCEPT-A · ligne 4617
2022* non éligible 2023* non éligible 2024* non éligible 2025* non éligible 2026* non éligible 2027* non éligible
RCEP B
B · ligne 4617
2022* non éligible 2023* non éligible 2024* non éligible 2025* non éligible 2026* non éligible 2027* non éligible
RCEP C
C · ligne 4617
2022* non éligible 2023* non éligible 2024* non éligible 2025* non éligible 2026* non éligible 2027* non éligible
RCEP D
D · ligne 4617
2022* non éligible 2023* non éligible 2024* non éligible 2025* non éligible 2026* non éligible 2027* non éligible
RCEP E
E · ligne 4620
2022* non éligible 2023* non éligible 2024* non éligible 2025* non éligible 2026* non éligible 2027* non éligible
RCEP F
F · ligne 4617
2022* non éligible 2023* non éligible 2024* non éligible 2025* non éligible 2026* non éligible 2027* non éligible
VIFTA
VI · ligne 4257
202412,6% 202511,2% 20269,8% 20278,4%
Colonne auxiliaire J: 8

* Les périodes CPTPP (I)–(VII) sont rattachées à des années par comparaison avec le BT2026 (données DÉRIVÉES – à vérifier).

Conseils et avertissements

Évaluation générale (origine non prise en compte). Lancez le Smart Tariff Advisory pour une évaluation propre à une origine.

YELLOW – REVIEW REQUIRED FTA-009 CPTPP: separate "M:" rate
Description
The CPTPP cell "2,7; M: 4" has a general 2,7% and an "M:" 4% rate (commonly read as the Mexico schedule – verify).
Référence juridique
115/2022/NĐ-CP
Action recommandée
Confirm the CPTPP schedule for the origin under Decree 115/2022/NĐ-CP.
Statut de vérification
Non vérifié – contrôle nécessaire
YELLOW – REVIEW REQUIRED FTA-010 Consolidated vs FTA schedule discrepancy
Description
CPTPP: consolidated BT2026 shows "2,7; M: 4", the FTA schedule for period (VI) shows "2,7".
Référence juridique
115/2022/NĐ-CP
Action recommandée
Check the original Decree and amendments to determine the correct rate.
Statut de vérification
Non vérifié – contrôle nécessaire
YELLOW – REVIEW REQUIRED FTA-013 FTA rate not lower than MFN
Description
VKFTA 14%, VN-LAO 14%: the preferential rate is equal to or higher than the MFN rate (14%) in the source tariff – claiming the FTA brings no saving.
Données liées
MFN 14%
Action recommandée
Consider the MFN rate (if the origin qualifies for MFN treatment) instead of preparing FTA origin documents.
Statut de vérification
Non vérifié – contrôle nécessaire
YELLOW – REVIEW REQUIRED HS-003 Classification Review Required – similar lines exist
Description
Subheading 3006.92 has 2 lines; 3006.92.90 is distinguished from its siblings by: Other.
Données liées
3006.92.10 Of medicaments for the treatment of cancer, HIV/AIDS or other intractable diseases
Référence juridique
31/2022/TT-BTC
Action recommandée
Verify the distinguishing features; consider an advance classification ruling if uncertain.
Statut de vérification
Non vérifié – contrôle nécessaire
YELLOW – REVIEW REQUIRED TAX-001 Several VAT rates
Description
The VAT column shows "5/8/10".
Référence juridique
181/2025/NĐ-CP
Action recommandée
Determine the VAT rate by the nature of goods and reduction rules (174/2025/NĐ-CP, Annex I/II).
Statut de vérification
Non vérifié – contrôle nécessaire
GRAY – DATA UNAVAILABLE TR-004 Not Assessed – Additional Regulatory Verification Required
Description
The source file records no trade remedy for 3006.92.90. This does NOT mean there is no risk.
Action recommandée
Check the MOIT Trade Remedies Authority database.
Statut de vérification
Non vérifié – contrôle nécessaire
GREEN – VERIFIED DQ-001 MFN rate present in the source
Description
The MFN rate 14% for 3006.92.90 was checked against BT2026 (cell BT2026!N4686), basis 26/2023/NĐ-CP.
Référence juridique
26/2023/NĐ-CP
Action recommandée
Verification scope: matched against source file version 2026.04.05; not a substitute for the legal text.
Statut de vérification
Vérifié par rapport au fichier tarifaire source

Notes de chapitre

Notes

1. This Chapter does not cover:

(a) Foods or beverages (such as dietetic, diabetic or fortified foods, food supplements, tonic beverages and mineral waters), other than nutritional preparations for intravenous administration (Section IV);

(b) Products, such as tablets, chewing gum or patches (transdermal systems), containing nicotine and intended to assist tobacco use cessation (heading 24.04);

(c) Plasters specially calcined or finely ground for use in dentistry (heading 25.20);

(d) Aqueous distillates or aqueous solutions of essential oils, suitable for medicinal uses (heading 33.01);

(e) Preparations of headings 33.03 to 33.07, even if they have therapeutic or prophylactic properties;

(f) Soap or other products of heading 34.01 containing added medicaments;

(g) Preparations with a basis of plaster for use in dentistry (heading 34.07);

(h) Blood albumin not prepared for therapeutic or prophylactic uses (heading 35.02); or

(ij) Diagnostic reagents of heading 38.22.

2. For the purposes of heading 30.02, the expression “immunological products” applies to peptides and proteins (other than goods of heading 29.37) which are directly involved in the regulation of immunological processes, such as monoclonal antibodies (MAB), antibody fragments, antibody conjugates and antibody fragment conjugates, interleukins, interferons (IFN), chemokines and certain tumor necrosis factors (TNF), growth factors (GF), hematopoietins and colony stimulating factors (CSF).

3. For the purposes of headings 30.03 and 30.04 and of Note 4 (d) to this Chapter, the following are to be treated:

(a) As unmixed products:

(1) Unmixed products dissolved in water;

(2) All goods of Chapter 28 or 29; and

(3) Simple vegetable extracts of heading 13.02, merely standardised or dissolved in any solvent;

(b) As products which have been mixed:

(1) Colloidal solutions and suspensions (other than colloidal sulphur);

(2) Vegetable extracts obtained by the treatment of mixtures of vegetable materials; and

(3) Salts and concentrates obtained by evaporating natural mineral waters.

4. Heading 30.06 applies only to the following, which are to be classified in that heading and in no other heading of the Nomenclature:

(a) Sterile surgical catgut, similar sterile suture materials (including sterile absorbable surgical or dental yarns) and sterile tissue adhesives for surgical wound closure;

(b) Sterile laminaria and sterile laminaria tents;

(c) Sterile absorbable surgical or dental haemostatics; sterile surgical or dental adhesion barriers, whether or not absorbable;

(d) Opacifying preparations for X-ray examinations and diagnostic reagents designed to be administered to the patient, being unmixed products put up in measured doses or products consisting of two or more ingredients which have been mixed together for such uses;

(e) Placebos and blinded (or double-blinded) clinical trial kits for use in recognised clinical trials, put up in measured doses, even if they might contain active medicaments;

(f) Dental cements and other dental fillings; bone reconstruction cements;

(g) First-aid boxes and kits;

(h) Chemical contraceptive preparations based on hormones, on other products of heading 29.37 or on spermicides;

(ij) Gel preparations designed to be used in human or veterinary medicine as a lubricant for parts of the body for surgical operations or physical examinations or as a coupling agent between the body and medical instruments;

(k) Waste pharmaceuticals, that is, pharmaceutical products which are unfit for their original intended purpose due to, for example, expiry of shelf life; and

(l) Appliances identifiable for ostomy use, that is, colostomy, ileostomy and urostomy pouches cut to shape and their adhesive wafers or faceplates.

Subheading Notes

1. For the purposes of subheadings 3002.13 and 3002.14, the following are to be treated:

(a) As unmixed products, pure products, whether or not containing impurities;

(b) As products which have been mixed:

(1) The products mentioned in (a) above dissolved in water or in other solvents;

(2) The products mentioned in (a) and (b) (1) above with an added stabiliser necessary for their preservation or transport; and

(3) The products mentioned in (a), (b) (1) and (b) (2) above with any other additive.

2. Subheadings 3003.60 and 3004.60 cover medicaments containing artemisinin (INN) for oral ingestion combined with other pharmaceutical active ingredients, or containing any of the following active principles, whether or not combined with other pharmaceutical active ingredients: amodiaquine (INN); artelinic acid or its salts; artenimol (INN); artemotil (INN); artemether (INN); artesunate (INN); chloroquine (INN); dihydroartemisinin (INN); lumefantrine (INN); mefloquine (INN); piperaquine (INN); pyrimethamine (INN) or sulfadoxine (INN).

(*): Dạng uống là dạng sử dụng qua đường miệng (ví dụ, nuốt, nhai, ngậm, đặt dưới lưỡi…)

(SEN): Tham khảo Chú giải bổ sung (SEN) của Danh mục Thuế quan hài hòa ASEAN (AHTN) 2022